Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration‐QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers

Andreas Becker(Merck KGaA, Darmstadt (Germany)), Andreas Johne(Merck KGaA, Darmstadt (Germany))

Clinical and Translational Science

October 25, 2019

10.1111/cts.12713

Cited by 35

Related Papers

No related papers found

Powered by citation graph analysis